MSF's publications are an expression of our belief in the principle of témoignage, or bearing witness, and the belief that we are accountable to those we work for and with. Sharing news about our activities and reflecting on them, offering critiques when necessary, are therefore crucial aspects of our work.

View and download these publications below.

To view the U.S. Annual Reports or International Activity Reports, please visit the Annual Reports page.

Country/Region

10.30.2014

A survey of TB diagnostic and treatment practices in eight countries, October 2014.

MSF briefing paper, December 2014

What began in 2011 in Syria as protests inspired by the Arab Spring has become an entrenched and bloody conflict that shows no sign of resolution. Today, with an estimated 200,000 people killed and 7.6 million people displaced within the country and 3.2 million refugees registered outside, Syria is seen as the world’s most grave humanitarian disaster. In the face of this crisis, the previously functioning health system has collapsed and scores of thousands of medical staff have fled.

Iraq experienced a dramatic surge in violence in 2014 that triggered successive large-scale waves of displacement. More than 2.6 million people are said to have fled war-torn the central and northern areas of Iraq, particularly Al-Anbar, Ninawa, Salah Al-Din, Kirkuk and Diyala governorates.

June 09, 2016

UN governments adopted a Political Declaration on Ending AIDS during the UN’s High-Level Meeting on Ending AIDS in New York on June 8, 2016, in which governments have committed to reaching 30 million people with HIV treatment by 2020.

June 02, 2016

India must resist pressure from US lawmakers and pharmaceutical industry groups to block access to key medicines for millions of people worldwide

May 10, 2016

Gilead Sciences has been seeking patents in India for the hepatitis C drug sofosbuvir. The patent applications have been challenged by groups of people living with hepatitis C and HIV through "pre-grant oppositions." The patent just granted by India’s patent office was initially rejected in January 2015, just before President Obama’s visit to India, which was seen as vexing the US. Gilead appealed the rejection and the patent has now been granted.

April 21, 2016

In advance of the next round of the Regional Comprehensive Economic Partnership (RCEP) negotiations starting in Perth, Australia, this Sunday, the international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) is warning that current proposals in this trade agreement could severely restrict access to affordable medicines for millions of people around the world. Text from a leaked chapter on intellectual property shows that Japan and South Korea have made proposals that go beyond what international trade rules require, undermining access to affordable generic medicines and making it harder for patients and treatment providers like MSF to access affordable, lifesaving medicines.

March 29, 2016

MSF urges Indian Prime Minister not to cave into pressure from EU to accept trade deal that could prevent millions of people from accessing lifesaving medicines

March 23, 2016

Since 2006, Doctors Without Borders/Médecins Sans Frontières (MSF) has been providing ambulatory medical and psychosocial care for people in Mumbai living with drug-resistant tuberculosis (DRTB), HIV, hepatitis C, or a combination of these diseases. The majority of the patients are HIV positive who require second or third line treatment. Narendra* is one of only two percent of drug-resistant TB patients in need that have access to these new drugs.

March 11, 2016

New York/New Delhi—Doctors Without Borders/Médecins Sans Frontières (MSF) has filed a "patent opposition" in India to block US pharmaceutical company Pfizer from patenting a pneumococcal conjugate vaccine, and ensure affordable access to this critical vaccine (PCV13). This is the first time a vaccine (biosimilar) patent has been challenged in India by a medical organization and, if successful, will make affordable versions of this lifesaving vaccine available to developing countries and humanitarian organizations.

February 26, 2016

New York/New Delhi—In proceedings that could have major implications for millions of people waiting for affordable access to a lifesaving hepatitis C drug, the Indian Patent Office this week began hearings to determine whether US pharmaceutical company Gilead Sciences deserves a patent for sofosbuvir, a hepatitis C drug for which the company currently charges $1,000 per pill in the US.

February 10, 2016

Delhi/New York—A patient living with HIV in India has filed an application to try to block ViiV Healthcare from being granted patents on two new critical HIV drugs, the medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) announced today.

September 29, 2015

On September 28, Doctors Without Borders/Médecins Sans Frontières' (MSF) took advantage of Indian Prime Minister Narendra Modi being in New York City to send him a message. Thanks to the country's patent laws, India is the pharmacy to the developing world; MSF sources 80% of its HIV drugs from India among other essential medicines. The U.S. is pressuring PM Modi to make India's patent laws more restrictive, which would benefit big pharma companies and cause millions of people to lose access to affordable medicines. MSF is urging PM Modi not to give in to U.S. pressure.

Pages